---
title: "H.C. Wainwright Reaffirms Their Buy Rating on Protagonist Therapeutics (PTGX)"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/265997094.md"
description: "H.C. Wainwright analyst Douglas Tsao reaffirmed a Buy rating for Protagonist Therapeutics with a price target of $80.00. Tsao, who covers the Healthcare sector, has an average return of 22.0% and a 53.85% success rate. Citi's Geoff Meacham also issued a Buy rating, while TR | OpenAI reiterated a Hold rating on Protagonist Therapeutics."
datetime: "2025-11-14T23:38:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/265997094.md)
  - [en](https://longbridge.com/en/news/265997094.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/265997094.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/265997094.md) | [English](https://longbridge.com/en/news/265997094.md)


# H.C. Wainwright Reaffirms Their Buy Rating on Protagonist Therapeutics (PTGX)

H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Protagonist Therapeutics today and set a price target of $80.00.

### Meet Your ETF AI Analyst

-   Discover how TipRanks' _ETF_ AI Analyst can help you make smarter investment decisions
-   Explore ETFs TipRanks' users love and see what insights the **_ETF_ AI Analyst** reveals about the ones you follow.

Tsao covers the Healthcare sector, focusing on stocks such as Protagonist Therapeutics, Hansa Biopharma AB, and Alkermes. According to TipRanks, Tsao has an average return of 22.0% and a 53.85% success rate on recommended stocks.

In addition to H.C. Wainwright, Protagonist Therapeutics also received a Buy from Citi’s Geoff Meacham in a report issued on November 10. However, on November 11, TR | OpenAI – 4o reiterated a Hold rating on Protagonist Therapeutics (NASDAQ: PTGX).

### 相關股票

- [Protagonist Therap (PTGX.US)](https://longbridge.com/zh-HK/quote/PTGX.US.md)

## 相關資訊與研究

- [Protagonist Therapeutics Insider Sold Shares Worth $2,520,000, According to a Recent SEC Filing](https://longbridge.com/zh-HK/news/280976343.md)
- [Protagonist Therapeutics Insider Sold Shares Worth $5,524,700, According to a Recent SEC Filing](https://longbridge.com/zh-HK/news/280593517.md)
- [3 Best ETFs to Invest In, According to AI Analyst, 03/31/2026](https://longbridge.com/zh-HK/news/281217554.md)
- [Is This the One ETF to Rule Them All?](https://longbridge.com/zh-HK/news/280916559.md)
- [HKEX on Expanding ETF Offerings](https://longbridge.com/zh-HK/news/280764173.md)